Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083)

Organon

Status and phase

Withdrawn

Phase 2

Conditions

Bone Neoplasms

Treatments

Drug: MK0663, etoricoxib / Duration of Treatment: 4 weeks

Study type

Interventional

Funder types

Industry

Identifiers

NCT00095017

2004_090

0663-083

Details and patient eligibility

About

The purpose of this study is to compare the effectiveness of an investigational drug versus placebo in the treatment of metastatic bone cancer pain in patients diagnosed with breast or prostate cancer and a bone neoplasm. Patients in the study will be taking opioids to treat moderate to severe pain for their bone metastases and will remain on their opioids during the entire course of the study.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Patients are required to have a diagnosis of breast or prostate cancer with bone involvement and moderate to severe pain that requires opioid treatment.